The WSE-listed medtech company, Medicalgorithmics, has signed an agreement with Greek company TeleNurse Plus, a pioneer in innovative telemedicine solutions and one of the largest distributors of telemedical equipment in Greece. TeleNurse Plus offers a wide range of diagnostic and therapeutic services. Thanks to this agreement, Medicalgorithmics’ latest products will now be available in the Greek market, including the DRP platform with innovative DRAI algorithms. These algorithms have been recognized as a leading solution in the DRAI Martini study conducted on 14,000 patients, recently published in the prestigious journal Nature Medicine.
Greece, due to its geographical characteristics – numerous islands and mountainous regions – is a market with significant potential in the field of telemedicine. This stems in part from ongoing challenges in accessing healthcare. Access to hospitals, particularly outside of Athens, ranks among the worst in the European Union, and 15 Greek regions are among the 97 least medically connected areas in the EU. In these regions, more than half of the residents have no hospital nearby. As a result, telemedicine, including telecardiology, is not only a necessity for providing basic medical care but is also steadily growing.
“As part of our growth strategy, we are increasing our presence in promising markets and signing further agreements. This allows us to introduce new generations of our innovative products to these markets – products that, thanks to the results of the DRAI Martini study published in Nature Medicine, are gaining increasing interest. We aim to fully leverage Medicalgorithmics’ rising recognition and are pleased with the growing trust in our brand and the breakthrough technologies we offer,” said Jarosław Jerzakowski, Management Board Member of Medicalgorithmics for Operations and Sales.
Greece is one of 24 markets where Medicalgorithmics’ innovative products are available. The WSE-listed medtech currently has agreements enabling its presence in: the USA, Canada, Australia, the Czech Republic, Slovakia, Slovenia, Poland, Austria, Switzerland, Italy, Denmark, Finland, Sweden, the United Kingdom, Armenia, Georgia, Turkey, India, the Philippines, Indonesia, Bahrain, Kuwait, Oman, and the United Arab Emirates.
Additionally, Medicalgorithmics’ innovative software is being used in clinical trials conducted in the USA, Canada, the UK, Poland, the Czech Republic, Germany, the Netherlands, Denmark, Norway, France, Italy, Greece, and Sweden. The company also plans to gradually increase its involvement in this area, supported by the expansion of its collaboration in early February this year with the Canadian research institute Population Health Research Institute (PHRI) – one of the world’s leading centers for clinical research.